Combination Antibody Therapy Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region:

Description

In a recent report released by it has been revealed that the chemotherapy/antibody segment of the global combination antibody therapy market is poised for remarkable growth over the forecast period. The segment, which accounted for nearly 40% of the market share by the end of 2031, is anticipated to exhibit a staggering Compound Annual Growth Rate (CAGR) of 8.5% in terms of value, projecting a valuation close to US$ 35 billion in 2024.

Rising Cancer Incidence to Drive Segment's Ascension

One of the primary drivers propelling the growth of the chemotherapy/antibody segment is the escalating incidence of cancer worldwide. With cancer ranking as the second leading cause of mortality globally, the toll it exacts on human lives has surged significantly in recent years. According to the World Health Organization (WHO), over 8 million deaths annually are attributed to cancer, with a forecast of nearly 70% increase in new cancer cases over the next two decades.

Unique Treatment Needs Call for Chemotherapy

Each type of cancer necessitates a tailored approach to treatment, and chemotherapy stands as a cornerstone in the fight against this relentless disease. The capability of chemotherapy to target cancer cells throughout the body addresses the urgent need for comprehensive treatment modalities, thus bolstering the growth of the chemotherapy/antibody segment.

Efficacy Reigns Supreme: Combination Antibody Therapies at the Helm

In contrast to conventional therapies like radiation or surgery, combination antibody therapies, particularly chemotherapy/antibody, have emerged as more efficacious alternatives. While radiation therapy and surgery predominantly target specific areas, combination antibody therapy operates systemically, ensuring a more comprehensive assault on cancer cells.

Awareness and Education: Catalysts for Growth

The burgeoning awareness among individuals regarding available cancer treatment options further fuels the expansion of the chemotherapy/antibody segment. As knowledge dissemination continues to grow, more individuals are empowered to make informed decisions regarding their healthcare, thereby driving demand for innovative therapies.

APAC Region Poised for Significant Value Uptick

While North America continues to dominate the chemotherapy/antibody segment, the APAC (Asia-Pacific) region is poised for exponential growth. With market shares exceeding 40% in Latin America and APAC, the chemotherapy/antibody segment is projected to experience a remarkable surge in the APAC region, reaching close to US$ 6 billion in 2024.

Key Players Pave the Way with Novel Therapies

In a bid to combat chronic Lymphocytic Leukemia (CLL), key players in the industry have unveiled groundbreaking combination drugs. Biogen Inc., a U.S.-based pharmaceutical company, made headlines in 2008 with the successful Phase III clinical trials of Rituxan. This drug, in combination with chemotherapy, demonstrated notable improvements in progression-free survival for patients with relapsed CLL. Subsequently, in 2010, the FDA approved Rituxan in combination with chemotherapy drugs such as fludarabine and cyclophosphamide (FC) for treating the most prevalent form of adult leukemia.

Market Dynamics: Key Players and Revenue Share

The global combination antibody therapy market is primarily dominated by the top 10 key players, who collectively contribute approximately 80% of the market's revenue share. This leaves the remaining players to account for the remaining 20% revenue share. Such dynamics underscore the significance of strategic partnerships and innovation in shaping the landscape of the combination antibody therapy market.

Key players in the market are:

Biogen Inc.
Roche Holdings AG
Seattle Genetics Inc.
Amgen incorporated
Bristol-Myers Squibb Company
Eli Lilly and Company
Novartis AG
Sanofi
Celgene Corp
Genmab A/S
Others.

Market segmentation

By combination, the market is segmented into:

Chemotherapy/Antibody
Antibody/Antibody
Conjugated Antibodies
Bispecific Antibodies

By application, the market is segmented into:

Lung Cancer
Blood Cancer
Lymphoma
Leukemia
Myeloma
Breast Cancer
Colorectal Cancer
Others

By end user, the market is segmented into:

Hospitals
Cancer research institutes
Clinics
ASCs

By region, the market is segmented into:

North America
Latin America
Europe
APAC
MEA

1. Executive Summary

1.1. Global Combination Antibody Therapy Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2023
1.5. Analyst Recommendations

2. Market Overview

2.1. Market Definitions and Segmentations
2.2. Market Dynamics
- 2.2.1. Drivers
- 2.2.2. Restraints
- 2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter's Five Forces Analysis
2.5. COVID-19 Impact Analysis
- 2.5.1. Supply
- 2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
- 2.7.1. World Economic Projections
2.8. PESTLE Analysis

3. Global Combination Antibody Therapy Market Outlook, 2018 - 2031

3.1. Global Combination Antibody Therapy Market Outlook, by Combination, Value (US$ Bn), 2018 - 2031
- 3.1.1. Key Highlights
  - 3.1.1.1. Chemotherapy/Antibody
  - 3.1.1.2. Antibody/Antibody
  - 3.1.1.3. Conjugated Antibodies
  - 3.1.1.4. Bispecific Antibodies
3.2. Global Combination Antibody Therapy Market Outlook, by Application, Value (US$ Bn), 2018 - 2031
- 3.2.1. Key Highlights
  - 3.2.1.1. Lung Cancer
  - 3.2.1.2. Blood Cancer
    - 3.2.1.2.1. Lymphoma
    - 3.2.1.2.2. Leukemia
    - 3.2.1.2.3. Myeloma
  - 3.2.1.3. Breast Cancer
  - 3.2.1.4. Colorectal Cancer
  - 3.2.1.5. Others
3.3. Global Combination Antibody Therapy Market Outlook, by End User, Value (US$ Bn), 2018 - 2031
- 3.3.1. Key Highlights
  - 3.3.1.1. Hospitals
  - 3.3.1.2. Cancer research institutes
  - 3.3.1.3. Clinics
  - 3.3.1.4. ASCs
3.4. Global Combination Antibody Therapy Market Outlook, by Region, Value (US$ Bn), 2018 - 2031
- 3.4.1. Key Highlights
  - 3.4.1.1. North America
  - 3.4.1.2. Europe
  - 3.4.1.3. Asia Pacific
  - 3.4.1.4. Latin America
  - 3.4.1.5. Middle East & Africa

4. North America Combination Antibody Therapy Market Outlook, 2018 - 2031

4.1. North America Combination Antibody Therapy Market Outlook, by Combination, Value (US$ Bn), 2018 - 2031
- 4.1.1. Key Highlights
  - 4.1.1.1. Chemotherapy/Antibody
  - 4.1.1.2. Antibody/Antibody
  - 4.1.1.3. Conjugated Antibodies
  - 4.1.1.4. Bispecific Antibodies
4.2. North America Combination Antibody Therapy Market Outlook, by Application, Value (US$ Bn), 2018 - 2031
- 4.2.1. Key Highlights
  - 4.2.1.1. Lung Cancer
  - 4.2.1.2. Blood Cancer
    - 4.2.1.2.1. Lymphoma
    - 4.2.1.2.2. Leukemia
    - 4.2.1.2.3. Myeloma
  - 4.2.1.3. Breast Cancer
  - 4.2.1.4. Colorectal Cancer
  - 4.2.1.5. Others
4.3. North America Combination Antibody Therapy Market Outlook, by End User, Value (US$ Bn), 2018 - 2031
- 4.3.1. Key Highlights
  - 4.3.1.1. Hospitals
  - 4.3.1.2. Cancer research institutes
  - 4.3.1.3. Clinics
  - 4.3.1.4. ASCs
- 4.3.2. BPS Analysis/Market Attractiveness Analysis
4.4. North America Combination Antibody Therapy Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 4.4.1. Key Highlights
  - 4.4.1.1. U.S. Combination Antibody Therapy Market by Combination, Value (US$ Bn), 2018 - 2031
  - 4.4.1.2. U.S. Combination Antibody Therapy Market by Application, Value (US$ Bn), 2018 - 2031
  - 4.4.1.3. U.S. Combination Antibody Therapy Market by End User, Value (US$ Bn), 2018 - 2031
  - 4.4.1.4. Canada Combination Antibody Therapy Market by Combination, Value (US$ Bn), 2018 - 2031
  - 4.4.1.5. Canada Combination Antibody Therapy Market by Application, Value (US$ Bn), 2018 - 2031
  - 4.4.1.6. Canada Combination Antibody Therapy Market by End User, Value (US$ Bn), 2018 - 2031
- 4.4.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Combination Antibody Therapy Market Outlook, 2018 - 2031

5.1. Europe Combination Antibody Therapy Market Outlook, by Combination, Value (US$ Bn), 2018 - 2031
- 5.1.1. Key Highlights
  - 5.1.1.1. Chemotherapy/Antibody
  - 5.1.1.2. Antibody/Antibody
  - 5.1.1.3. Conjugated Antibodies
  - 5.1.1.4. Bispecific Antibodies
5.2. Europe Combination Antibody Therapy Market Outlook, by Application, Value (US$ Bn), 2018 - 2031
- 5.2.1. Key Highlights
  - 5.2.1.1. Lung Cancer
  - 5.2.1.2. Blood Cancer
    - 5.2.1.2.1. Lymphoma
    - 5.2.1.2.2. Leukemia
    - 5.2.1.2.3. Myeloma
  - 5.2.1.3. Breast Cancer
  - 5.2.1.4. Colorectal Cancer
  - 5.2.1.5. Others
5.3. Europe Combination Antibody Therapy Market Outlook, by End User, Value (US$ Bn), 2018 - 2031
- 5.3.1. Key Highlights
  - 5.3.1.1. Hospitals
  - 5.3.1.2. Cancer research institutes
  - 5.3.1.3. Clinics
  - 5.3.1.4. ASCs
- 5.3.2. BPS Analysis/Market Attractiveness Analysis
5.4. Europe Combination Antibody Therapy Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 5.4.1. Key Highlights
  - 5.4.1.1. Germany Combination Antibody Therapy Market by Combination, Value (US$ Bn), 2018 - 2031
  - 5.4.1.2. Germany Combination Antibody Therapy Market by Application, Value (US$ Bn), 2018 - 2031
  - 5.4.1.3. Germany Combination Antibody Therapy Market by End User, Value (US$ Bn), 2018 - 2031
  - 5.4.1.4. U.K. Combination Antibody Therapy Market by Combination, Value (US$ Bn), 2018 - 2031
  - 5.4.1.5. U.K. Combination Antibody Therapy Market by Application, Value (US$Bn), 2018 - 2031
  - 5.4.1.6. U.K. Combination Antibody Therapy Market by End User, Value (US$ Bn), 2018 - 2031
  - 5.4.1.7. France Combination Antibody Therapy Market by Combination, Value (US$ Bn), 2018 - 2031
  - 5.4.1.8. France Combination Antibody Therapy Market by Application, Value (US$ Bn), 2018 - 2031
  - 5.4.1.9. France Combination Antibody Therapy Market by End User, Value (US$ Bn), 2018 - 2031
  - 5.4.1.10. Italy Combination Antibody Therapy Market by Combination, Value (US$ Bn), 2018 - 2031
  - 5.4.1.11. Italy Combination Antibody Therapy Market by Application, Value (US$ Bn), 2018 - 2031
  - 5.4.1.12. Italy Combination Antibody Therapy Market by End User, Value (US$ Bn), 2018 - 2031
  - 5.4.1.13. Turkey Combination Antibody Therapy Market by Combination, Value (US$ Bn), 2018 - 2031
  - 5.4.1.14. Turkey Combination Antibody Therapy Market by Application, Value (US$ Bn), 2018 - 2031
  - 5.4.1.15. Turkey Combination Antibody Therapy Market by End User, Value (US$ Bn), 2018 - 2031
  - 5.4.1.16. Russia Combination Antibody Therapy Market by Combination, Value (US$ Bn), 2018 - 2031
  - 5.4.1.17. Russia Combination Antibody Therapy Market by Application, Value (US$ Bn), 2018 - 2031
  - 5.4.1.18. Russia Combination Antibody Therapy Market by End User, Value (US$ Bn), 2018 - 2031
  - 5.4.1.19. Rest of Europe Combination Antibody Therapy Market by Combination, Value (US$ Bn), 2018 - 2031
  - 5.4.1.20. Rest of Europe Combination Antibody Therapy Market by Application, Value (US$ Bn), 2018 - 2031
  - 5.4.1.21. Rest of Europe Combination Antibody Therapy Market by End User, Value (US$ Bn), 2018 - 2031
- 5.4.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Combination Antibody Therapy Market Outlook, 2018 - 2031

6.1. Asia Pacific Combination Antibody Therapy Market Outlook, by Combination, Value (US$ Bn), 2018 - 2031
- 6.1.1. Key Highlights
  - 6.1.1.1. Chemotherapy/Antibody
  - 6.1.1.2. Antibody/Antibody
  - 6.1.1.3. Conjugated Antibodies
  - 6.1.1.4. Bispecific Antibodies
6.2. Asia Pacific Combination Antibody Therapy Market Outlook, by Application, Value (US$ Bn), 2018 - 2031
- 6.2.1. Key Highlights
  - 6.2.1.1. Lung Cancer
  - 6.2.1.2. Blood Cancer
    - 6.2.1.2.1. Lymphoma
    - 6.2.1.2.2. Leukemia
    - 6.2.1.2.3. Myeloma
  - 6.2.1.3. Breast Cancer
  - 6.2.1.4. Colorectal Cancer
  - 6.2.1.5. Others
6.3. Asia Pacific Combination Antibody Therapy Market Outlook, by End User, Value (US$ Bn), 2018 - 2031
- 6.3.1. Key Highlights
  - 6.3.1.1. Hospitals
  - 6.3.1.2. Cancer research institutes
  - 6.3.1.3. Clinics
  - 6.3.1.4. ASCs
- 6.3.2. BPS Analysis/Market Attractiveness Analysis
6.4. Asia Pacific Combination Antibody Therapy Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 6.4.1. Key Highlights
  - 6.4.1.1. China Combination Antibody Therapy Market by Combination, Value (US$ Bn), 2018 - 2031
  - 6.4.1.2. China Combination Antibody Therapy Market by Application, Value (US$ Bn), 2018 - 2031
  - 6.4.1.3. China Combination Antibody Therapy Market by End User, Value (US$ Bn), 2018 - 2031
  - 6.4.1.4. Japan Combination Antibody Therapy Market by Combination, Value (US$ Bn), 2018 - 2031
  - 6.4.1.5. Japan Combination Antibody Therapy Market by Application, Value (US$ Bn), 2018 - 2031
  - 6.4.1.6. Japan Combination Antibody Therapy Market by End User, Value (US$ Bn), 2018 - 2031
  - 6.4.1.7. South Korea Combination Antibody Therapy Market by Combination, Value (US$ Bn), 2018 - 2031
  - 6.4.1.8. South Korea Combination Antibody Therapy Market by Application, Value (US$ Bn), 2018 - 2031
  - 6.4.1.9. South Korea Combination Antibody Therapy Market by End User, Value (US$ Bn), 2018 - 2031
  - 6.4.1.10. India Combination Antibody Therapy Market by Combination, Value (US$ Bn), 2018 - 2031
  - 6.4.1.11. India Combination Antibody Therapy Market by Application, Value (US$ Bn), 2018 - 2031
  - 6.4.1.12. India Combination Antibody Therapy Market by End User, Value (US$ Bn), 2018 - 2031
  - 6.4.1.13. Southeast Asia Combination Antibody Therapy Market by Combination, Value (US$ Bn), 2018 - 2031
  - 6.4.1.14. Southeast Asia Combination Antibody Therapy Market by Application, Value (US$ Bn), 2018 - 2031
  - 6.4.1.15. Southeast Asia Combination Antibody Therapy Market by End User, Value (US$ Bn), 2018 - 2031
  - 6.4.1.16. Rest of Asia Pacific Combination Antibody Therapy Market by Combination, Value (US$ Bn), 2018 - 2031
  - 6.4.1.17. Rest of Asia Pacific Combination Antibody Therapy Market by Application, Value (US$ Bn), 2018 - 2031
  - 6.4.1.18. Rest of Asia Pacific Combination Antibody Therapy Market by End User, Value (US$ Bn), 2018 - 2031
- 6.4.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Combination Antibody Therapy Market Outlook, 2018 - 2031

7.1. Latin America Combination Antibody Therapy Market Outlook, by Combination, Value (US$ Bn), 2018 - 2031
- 7.1.1. Key Highlights
  - 7.1.1.1. Chemotherapy/Antibody
  - 7.1.1.2. Antibody/Antibody
  - 7.1.1.3. Conjugated Antibodies
  - 7.1.1.4. Bispecific Antibodies
7.2. Latin America Combination Antibody Therapy Market Outlook, by Application, Value (US$ Bn), 2018 - 2031
- 7.2.1. Key Highlights
  - 7.2.1.1. Lung Cancer
  - 7.2.1.2. Blood Cancer
    - 7.2.1.2.1. Lymphoma
    - 7.2.1.2.2. Leukemia
    - 7.2.1.2.3. Myeloma
  - 7.2.1.3. Breast Cancer
  - 7.2.1.4. Colorectal Cancer
  - 7.2.1.5. Others
7.3. Latin America Combination Antibody Therapy Market Outlook, by End User, Value (US$ Bn), 2018 - 2031
- 7.3.1. Key Highlights
  - 7.3.1.1. Hospitals
  - 7.3.1.2. Cancer research institutes
  - 7.3.1.3. Clinics
  - 7.3.1.4. ASCs
- 7.3.2. BPS Analysis/Market Attractiveness Analysis
7.4. Latin America Combination Antibody Therapy Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 7.4.1. Key Highlights
  - 7.4.1.1. Brazil Combination Antibody Therapy Market by Combination, Value (US$ Bn), 2018 - 2031
  - 7.4.1.2. Brazil Combination Antibody Therapy Market by Application, Value (US$ Bn), 2018 - 2031
  - 7.4.1.3. Brazil Combination Antibody Therapy Market by End User, Value (US$ Bn), 2018 - 2031
  - 7.4.1.4. Mexico Combination Antibody Therapy Market by Combination, Value (US$ Bn), 2018 - 2031
  - 7.4.1.5. Mexico Combination Antibody Therapy Market by Application, Value (US$ Bn), 2018 - 2031
  - 7.4.1.6. Mexico Combination Antibody Therapy Market by End User, Value (US$ Bn), 2018 - 2031
  - 7.4.1.7. Argentina Combination Antibody Therapy Market by Combination, Value (US$ Bn), 2018 - 2031
  - 7.4.1.8. Argentina Combination Antibody Therapy Market by Application, Value (US$ Bn), 2018 - 2031
  - 7.4.1.9. Argentina Combination Antibody Therapy Market by End User, Value (US$ Bn), 2018 - 2031
  - 7.4.1.10. Rest of Latin America Combination Antibody Therapy Market by Combination, Value (US$ Bn), 2018 - 2031
  - 7.4.1.11. Rest of Latin America Combination Antibody Therapy Market by Application, Value (US$ Bn), 2018 - 2031
  - 7.4.1.12. Rest of Latin America Combination Antibody Therapy Market by End User, Value (US$ Bn), 2018 - 2031
- 7.4.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Combination Antibody Therapy Market Outlook, 2018 - 2031

8.1. Middle East & Africa Combination Antibody Therapy Market Outlook, by Combination, Value (US$ Bn), 2018 - 2031
- 8.1.1. Key Highlights
  - 8.1.1.1. Chemotherapy/Antibody
  - 8.1.1.2. Antibody/Antibody
  - 8.1.1.3. Conjugated Antibodies
  - 8.1.1.4. Bispecific Antibodies
8.2. Middle East & Africa Combination Antibody Therapy Market Outlook, by Application, Value (US$ Bn), 2018 - 2031
- 8.2.1. Key Highlights
  - 8.2.1.1. Lung Cancer
  - 8.2.1.2. Blood Cancer
    - 8.2.1.2.1. Lymphoma
    - 8.2.1.2.2. Leukemia
    - 8.2.1.2.3. Myeloma
  - 8.2.1.3. Breast Cancer
  - 8.2.1.4. Colorectal Cancer
  - 8.2.1.5. Others
8.3. Middle East & Africa Combination Antibody Therapy Market Outlook, by End User, Value (US$ Bn), 2018 - 2031
- 8.3.1. Key Highlights
  - 8.3.1.1. Hospitals
  - 8.3.1.2. Cancer research institutes
  - 8.3.1.3. Clinics
  - 8.3.1.4. ASCs
- 8.3.2. BPS Analysis/Market Attractiveness Analysis
8.4. Middle East & Africa Combination Antibody Therapy Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 8.4.1. Key Highlights
  - 8.4.1.1. GCC Combination Antibody Therapy Market by Combination, Value (US$ Bn), 2018 - 2031
  - 8.4.1.2. GCC Combination Antibody Therapy Market by Application, Value (US$ Bn), 2018 - 2031
  - 8.4.1.3. GCC Combination Antibody Therapy Market by End User, Value (US$ Bn), 2018 - 2031
  - 8.4.1.4. South Africa Combination Antibody Therapy Market by Combination, Value (US$ Bn), 2018 - 2031
  - 8.4.1.5. South Africa Combination Antibody Therapy Market by Application, Value (US$ Bn), 2018 - 2031
  - 8.4.1.6. South Africa Combination Antibody Therapy Market by End User, Value (US$ Bn), 2018 - 2031
  - 8.4.1.7. Egypt Combination Antibody Therapy Market by Combination, Value (US$ Bn), 2018 - 2031
  - 8.4.1.8. Egypt Combination Antibody Therapy Market by Application, Value (US$ Bn), 2018 - 2031
  - 8.4.1.9. Egypt Combination Antibody Therapy Market by End User, Value (US$ Bn), 2018 - 2031
  - 8.4.1.10. Nigeria Combination Antibody Therapy Market by Combination, Value (US$ Bn), 2018 - 2031
  - 8.4.1.11. Nigeria Combination Antibody Therapy Market by Application, Value (US$ Bn), 2018 - 2031
  - 8.4.1.12. Nigeria Combination Antibody Therapy Market by End User, Value (US$ Bn), 2018 - 2031
  - 8.4.1.13. Rest of Middle East & Africa Combination Antibody Therapy Market by Combination, Value (US$ Bn), 2018 - 2031
  - 8.4.1.14. Rest of Middle East & Africa Combination Antibody Therapy Market by Application, Value (US$ Bn), 2018 - 2031
  - 8.4.1.15. Rest of Middle East & Africa Combination Antibody Therapy Market by End User, Value (US$ Bn), 2018 - 2031
- 8.4.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

9.1. By Component vs by Application Heat map
9.2. Company Market Share Analysis, 2023
9.3. Competitive Dashboard
9.4. Company Profiles
- 9.4.1. Biogen Inc.
  - 9.4.1.1. Company Overview
  - 9.4.1.2. Product Portfolio
  - 9.4.1.3. Financial Overview
  - 9.4.1.4. Business Strategies and Development
- 9.4.2. Roche Holdings AG
  - 9.4.2.1. Company Overview
  - 9.4.2.2. Product Portfolio
  - 9.4.2.3. Financial Overview
  - 9.4.2.4. Business Strategies and Development
- 9.4.3. Seattle Genetics Inc.
  - 9.4.3.1. Company Overview
  - 9.4.3.2. Product Portfolio
  - 9.4.3.3. Financial Overview
  - 9.4.3.4. Business Strategies and Development
- 9.4.4. Amgen incorporated
  - 9.4.4.1. Company Overview
  - 9.4.4.2. Product Portfolio
  - 9.4.4.3. Financial Overview
  - 9.4.4.4. Business Strategies and Development
- 9.4.5. Bristol-Myers Squibb Company
  - 9.4.5.1. Company Overview
  - 9.4.5.2. Product Portfolio
  - 9.4.5.3. Financial Overview
  - 9.4.5.4. Business Strategies and Development
- 9.4.6. Eli Lilly and Company
  - 9.4.6.1. Company Overview
  - 9.4.6.2. Product Portfolio
  - 9.4.6.3. Financial Overview
  - 9.4.6.4. Business Strategies and Development
- 9.4.7. Novartis AG
  - 9.4.7.1. Company Overview
  - 9.4.7.2. Product Portfolio
  - 9.4.7.3. Financial Overview
  - 9.4.7.4. Business Strategies and Development
- 9.4.8. Sanofi
  - 9.4.8.1. Company Overview
  - 9.4.8.2. Product Portfolio
  - 9.4.8.3. Financial Overview
  - 9.4.8.4. Business Strategies and Development
- 9.4.9. Celgene Corp
  - 9.4.9.1. Company Overview
  - 9.4.9.2. Product Portfolio
  - 9.4.9.3. Financial Overview
  - 9.4.9.4. Business Strategies and Development
- 9.4.10. Genmab A/S
  - 9.4.10.1. Company Overview
  - 9.4.10.2. Product Portfolio
  - 9.4.10.3. Financial Overview
  - 9.4.10.4. Business Strategies and Development

10. Appendix

10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations